Footnotes, July/August 2004, Vol. 28, no. 7-9

Monthly newsletter of the State Library

Report of Recommendations to the University of Northern Iowa on a Review of Selected General and Application Controls over the Modern Executive Management Financial Information System, June 7, 2004 through July 29, 2004

State University Audit Report

A-7, Statistical Report On FIP Applications And Cases Discontinued, September 2004

Statistical Report On FIP Applications And Cases Discontinued

A-7, Statistical Report On FIP Applications And Cases Discontinued, October 2004

Statistical Report On FIP Applications And Cases Discontinued

Iowa 100% E News, October/November 2001, Vol.1, no.7

Newsletter for the Information Technology Department

The Security Blanket, March 2002, Vol.1, no.7

Newsletter for Information Technology Department

13-7-19, le cénotaphe, arc de triomphe [place de l'Etoile, foule nombreuse] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54866

13-7-19, le cénotaphe, place de l'Etoile : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54865

13-7-19, Arc de triomphe de l'Etoile [édification du cénotaphe, foule importante] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54859

A-7 Statistical Report On FIP Applications And Cases Discontinued, November 2004

A-7 Statistical Report On FIP Applications And Cases Discontinued

ABD e-News, January 7, 2005

Weekly Newsletter

A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety.

AIMS: To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin®) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV). METHODS: This was a multinational, multicenter, single-blind, randomized trial in 15 centers, including 321 women. They were randomized to either vaginal DQC tablets or vaginal CLM cream. Follow-up visits were 1 week and 1 month after treatment. Clinical cure based on Amsel's criteria was the primary outcome. Secondary outcomes were rate of treatment failures and recurrences, incidence of post-treatment vulvovaginal candidosis (VVC), lactobacillary grade (LBG), total symptom score (TSC), and safety. RESULTS: Cure rates with DQC (C1: 81.5%, C2: 79.5%) were as high as with CLM (C1: 78.4%, C2: 77.6%). Thus, the treatment with DQC had equal efficacy as CLM cream. A trend to less common post-treatment VVC in the DQC-treated women was observed (DQC: 2.5%, CLM: 7.7%; p = 0.06). Both treatments were well tolerated with no serious adverse events occurring. CONCLUSION: Vaginal DQC has been shown to be equally effective as CLM cream, to be well tolerated with no systemic safety concerns, and is therefore a valid alternative therapy for women with BV [ClinicalTrials.gov, Med380104, NCT01125410].

A-7 Statistical Report On FIP Applications And Cases Discontinued, November 2004 (Revised)

Statistical Report On FIP Applications And Cases Discontinued

A-7 Statistical Report On FIP Applications And Cases Discontinued, December 2004

Statistical Report On FIP Applications And Cases Discontinued

A-7, Statistical Report On FIP Applications And Cases Discontinued, November 2004

Statistical Report On FIP Applications And Cases Discontinued